Acquired by Actavis in 2014 for US$28 billion. Actavis became a part of Israeli generics manufacturer Teva in 2016.
|Forest Laboratories Inc||USA||website|
| Actavis plc
owns 100% of Forest Laboratories Inc
|Forest Laboratories Inc|
In 2009, the U.S. Department of Justice accused Forest Labs of marketing Lexapro for unapproved uses, failing to disclose negative results from clinical trials and paying kickbacks to doctors who prescribed the drug. In 2010, this company's US subsidiary, Forest Pharmaceuticals Inc., agreed to pay more than $313 million to settle the charges over Lexapro and two other drugs, Levothroid and Celexa. Lexapro has been linked to serious birth defects. More lawsuits are pending.
[Source 2012][More on Irresponsible marketing]
This company received a score of 0/100 in the Newsweek Green Rankings 2014, which ranks the world's largest publicly traded companies on eight indicators covering energy, greenhouse gases, water, waste, fines and penalties, linking executive pay to sustainability targets, board-level committee oversight of environmental issues and third-party audits. Ranking methodology by Corporate Knights.
[Source 2014][More on Sustainability Reporting]
OpenSecrets.org tracks the influence of money on U.S. politics, and how that money affects policy and citizens' lives. Follow link to see this company's record of political donations, lobbying, outside spending and more.
|No assessment data currently available for Actavis plc|
|Company Structure||Wholly-owned subsidiary|
|Revenue||US$4.2 billion in 2010|
|# Employees||5,200 in 2010|
|Address||New York, USA|